Golar LNG Limited, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm

Investors with losses are encouraged to contact the firm before November 23, 2020; click


here


to submit trade information

​LOS ANGELES, Nov. 20, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Golar LNG Limited (NASDAQ: GLNG) investors that acquired shares between April 30, 2020 and August 10, 2020. Investors have until November 23, 2020 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in this complaint that throughout the Class Period, Golar made materially misleading and false statements in regard to their business, operations and prospects. Specifically, Golar failed to disclose and/or misrepresented to investors: (1) that certain employees, including Golar’s CEO, had bribed third parties, violating anti-bribery policies; (2) that, as a result, it was likely that Golar would face regulatory scrutiny and possible penalties; (3) that, as a result of the foregoing reputational harm, Golar’s valuation ahead of its IPO would be impaired significantly; and (4) that, as a result of the foregoing, Golar’s positive statements about the their business, operations, and prospects were lacked a reasonable basis. and/or materially misleading.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 23, 2020.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising



Jushi Holdings Inc. Increases Equity Ownership Interest in Dalitso LLC, the Company’s Majority-Owned, Virginia-Based Pharmaceutical Processor Permit Holder

Jushi Holdings Inc. Increased Equity Ownership Interest in Dalitso LLC to 79%

BOCA RATON, Fla., Nov. 20, 2020 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCMKTS: JUSHF), a vertically integrated, multi-state cannabis operator, announced it has purchased an additional 17.235% of the issued and outstanding equity of Dalitso LLC (Dalitso), a Virginia-based pharmaceutical processor. The Company now owns 79% of the issued and outstanding equity of Dalitso.

Dalitso is one of only five applicants to have received conditional approval for a pharmaceutical processor permit issued by the Virginia Board of Pharmacy, and one of only four to have received final approval and permit issuance in the Commonwealth. Dalitso’s permit allows the Dalitso to cultivate, process, dispense and deliver medical cannabis to registered patients in Virginia. The designated area for Dalitso to operate is Health Service Area II, in Northern Virginia. Dalitso has completed the initial build out of its cultivation, manufacturing, and processing footprint while also prefabricating the remaining 90,000 square foot facility in Prince William County, Virginia to allow for efficient scaling as patient demand increases.


Jim Cacioppo, Chief Executive Officer, Chairman and Founder of Jushi
said: “The Dalitso seed-to-sale facility will seamlessly integrate our cultivation, manufacturing, processing, and retail capabilities in Virginia. Between the expansion of our ownership stake in Dalitso and the enactment of new legislation earlier this year, we will be in a strong early mover position to drive value for our shareowners while serving patients in the most densely populated part of the Commonwealth.”

According to the U.S. Census Bureau, Health Service Area II has a population of approximately 2.5 million people or nearly 30% of the state population. This area includes two of Virginia’s most densely populated and highest-income counties, Fairfax County and Prince William County.

About Jushi Holdings Inc.

We are a vertically integrated cannabis company led by an industry-leading management team. In the United States, Jushi is focused on building a multi-state portfolio of branded cannabis assets through opportunistic acquisitions, distressed workouts and competitive applications. Jushi strives to maximize shareholder value while delivering high-quality products across all levels of the cannabis ecosystem. For more information please visit www.jushico.com or our social media channels, Instagram, Facebook, Twitter and LinkedIn.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, involve estimates, projections, plans, goals, forecasts and assumptions that may prove to be inaccurate. As a result, actual results could differ materially from those expressed by such forward-looking statements and such statements should not be relied upon. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or may contain statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “will continue,” “will occur” or “will be achieved”.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has certain expectations and has made certain assumptions. Key expectations and assumptions made by the Company include, but are not limited to: the continued performance of existing operations in Pennsylvania, Illinois and Nevada, the anticipated opening of additional dispensaries in 2020 and 2021, the expansion and optimization of the grower-processor in Pennsylvania and the facility in Nevada, the opening of new facilities in Ohio and Virginia and two dispensaries in California, which are subject to licensing approval. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: the ability of Jushi to successfully achieve business objectives, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; and compliance with extensive government regulation, as well as other risks and uncertainties which are more fully described in the Company’s Management, Discussion and Analysis for the six months ended June 30, 2020, and other filings with securities and regulatory authorities which are available at www.sedar.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.


Not for distribution to United States newswire services or for dissemination in the United States.

For further information, please contact:

Investor Relations Contact:

Michael Perlman
Executive Vice President of Investor Relations and Treasury
561-453-1308
[email protected] 

Media Contact:

Ellen Mellody
MATTIO Communications
570-209-2947
[email protected]



IIROC Trading Halt – APX

Canada NewsWire

VANCOUVER, BC, Nov. 20, 2020 /CNW/ – The following issues have been halted by IIROC:

Company: Apex Resources Inc.

TSX-Venture Symbol: APX

All Issues: Yes

Reason: Cease Trade Order

Halt Time (ET): 7:45 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

IIROC Trading Halt – MILE

Canada NewsWire

VANCOUVER, BC, Nov. 20, 2020 /CNW/ – The following issues have been halted by IIROC:

Company: Last Mile Holdings Ltd.

TSX-Venture Symbol: MILE

All Issues: Yes

Reason: At the Request of the Company Pending News

Halt Time (ET): 7:45 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

Extended Stay America Welcomes Seven New Properties

CHARLOTTE, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) — Extended Stay America, Inc. (NASDAQ:STAY), the largest mid-priced extended-stay hotel brand, announced today the addition of seven properties through franchise conversions. The properties are all owned by New York-based Three Wall Capital (TWC) and will be operated by Dallas, Texas-based Aimbridge Hospitality, the nation’s largest management company.

The properties include:

  • Extended Stay America Virginia Beach, Virginia Beach, Virginia
  • Extended Stay America Newport News – Yorktown, Newport News, Virginia
  • Extended Stay America Richmond – Glen Allen – Short Pump, Glen Allen, Virginia
  • Extended Stay America Chantilly – Dulles, Chantilly Virginia
  • Extended Stay America Atlanta – Norcross, Norcross, Georgia
  • Extended Stay America Atlanta – Northlake, Northlake, Georgia
  • Extended Stay America Chicago – Elgin – West Dundee, West Dundee, Illinois.

All of the hotels are well-positioned in their markets and within close proximity to retail, office, hospital, airports, and major highways. They will all feature complimentary Wi-Fi, premium cable, a STAYFIT fitness room, and a STAYCLEAN laundry room. The rooms include fully equipped kitchens with full-size refrigerators, stovetop, cookware, utensils, and dishes, as well as pillowtop beds, recliners, spacious workspace, and television streaming capabilities.

“We are extremely excited to be announcing the addition of seven conversions into the ESA brand,” said Judi Bikulege, Chief Investment Officer, Extended Stay America. “These new ESA locations continue our strategy of growing the ESA portfolio through franchising and the opportunity to do so through conversions of existing hotels as well as new construction. We look forward to continuing to work with Three Wall Capital and Aimbridge, as well as all of our current and prospective owners to continue growing our brand throughout the United States.”

TWC was the first Extended Stay America franchisee through the acquisition of 25 existing ESA hotels across the Midwest and Texas. “We viewed this acquisition not only as an opportunity to acquire strategically located assets and grow our extended-stay portfolio, but we were also thrilled to be able to work with ESA and build upon our strong existing relationship,” remarked Alan Kanders, Managing Member and Founder Three Wall Capital. “The strength of the ESA brand and the support of the ESA and Aimbridge teams helped us complete this transaction in the midst of the COVID-19 pandemic.”

TWC engaged Aimbridge Hospitality as the third-party manager of the portfolio, who is an experienced operator in the extended-stay space and currently operates 21 extended stay hotels for TWC. “Our extended stay team is excited to manage this exceptional collection of properties, and to continue to grow our partnership with Three Wall Capital and Extended Stay America,” said Mike Deitemeyer, Global President of Aimbridge Hospitality. “Our deep understanding of extended stay properties, along with our vertical specialists who understand the nuance of operating this category, is a tremendous advantage to owners and in driving each property’s market success.”


About Extended Stay America



®



Extended Stay America, Inc. and its brand Extended Stay America® is the leading brand in the mid-priced extended-stay segment in the U.S. with 646 hotels. Extended Stay America’s subsidiary, ESH Hospitality, Inc. (“ESH”), is the largest lodging REIT in North America by unit and room count, with 563 hotels and more than 62,000 rooms in the U.S. Extended Stay America also manages or franchises an additional 84 Extended Stay America® hotels.

For franchise inquiries, visit www.newesa.com for more information
For investor or media inquiries, contact Rob Ballew at [email protected] or 980-345-1546


About Aimbridge Hospitality


Aimbridge Hospitality is the leading, global third-party hotel management company operating branded full service, select service, luxury hotels, destination resorts, convention centers, and lifestyle hotels. Aimbridge merged with Interstate Hotels & Resorts in 2019 and now represents a premium portfolio of over 1,500 branded and independent properties in 49 states and 20 countries, inclusive of pipeline. Aimbridge is based in Plano, Texas and has additional corporate offices in Atlanta, Calgary, Fargo, Puerto Rico, San Clemente, Toronto, and Washington D.C. Aimbridge’s International Division, Interstate Hotels & Resorts, has supporting offices spread across Europe in Amsterdam, Birmingham, Glasgow, and Moscow.
For more information on Aimbridge Hospitality, please visit and connect with Aimbridge on LinkedIn.


About Three Wall Capital


Founded in 2008 by Alan Kanders, Three Wall Capital has completed over $1.0 billion in transactions in a principal investor capacity since inception. TWC invests with the philosophy that hotel real estate is subject to both short and long term cycles, and therefore, opportunistically invests in product type ranging from limited service to luxury hotels. TWC’s current investment strategy is to acquire and develop mid- scale extended stay hotels in markets with strong growth outlooks in terms of population, disposable income, jobs, diversity of high-quality food and beverage experiences, retail offerings, and office space. Three Wall Capital’s portfolio consists of 61 hotels across 12 states.
For further information and more details on TWC’s portfolio, visit www.threewallcapital.com



Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting

  • BDTX-1535 nominated as development candidate with IND-enabling studies underwa
    y
  • Pre-clinical data support
    novel and differentiated approach in GBM

CAMBRIDGE, Mass. and NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) —  Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the nomination of BDTX-1535 as the Company’s development candidate for the treatment of glioblastoma multiforme (GBM), as well as the commencement of Investigational New Drug (IND)-enabling studies.

Additionally, Black Diamond Therapeutics today announced a presentation at the 2020 Society for Neuro-Oncology Annual Meeting (SNO) of the pre-clinical data for BDTX-1535 and the biological rationale for a MasterKey approach to treating GBM patients whose tumors harbor allosteric oncogenic mutations in epidermal growth factor receptor (EGFR).

“These pre-clinical data demonstrate the achievement of our program’s key design principles, including potent and selective inhibition of the family of EGFR variants implicated in GBM and penetration of the blood-brain barrier, and further support our ability to develop a novel and differentiated candidate for the treatment of this disease,” said Elizabeth Buck, Ph.D., Executive Vice President, Discovery and Translational Sciences at Black Diamond Therapeutics. “This profile, coupled with the in vivo data that showed tumor growth inhibition in intracranial patient-derived xenograft (PDX) tumor models expressing allosteric EGFR mutants, supports the potential for BDTX-1535 to meaningfully transform the treatment paradigm for patients with GBM.”

GBM tumors express a family of allosteric oncogenic EGFR variants that often appear together in GBM and, as shown by the Company’s pre-clinical work, must all be effectively inhibited to secure a meaningful anti-tumor response. In cell-based assays, BDTX-1535 achieved potent MasterKey inhibition of all members of the family of oncogenic EGFR variants expressed in GBM with selectivity v. wild-type-EGFR (WT-EGFR). Additionally, in mouse models, BDTX-1535 demonstrated a pharmacokinetic profile that supports its ability to penetrate the blood-brain barrier. BDTX-1535 achieved complete and sustained inhibition of the phosphorylated state of EGFR in mouse models bearing Ba/F3 allosteric EGFR mutants, as well as tumor growth inhibition in mouse models bearing intracranial PDX tumors expressing allosteric EGFR mutants.

“Glioblastoma places an enormous burden on patients and their families, and we’re encouraged by these pre-clinical data that support BDTX-1535’s potential to improve treatment options for those impacted by GBM. The advancement of BDTX-1535 into early development is a critical step in our pursuit of a truly innovative approach for the treatment of this devastating disease,” said David M. Epstein, Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics. “We remain committed to the broad deployment of our proprietary MAP platform to produce novel MasterKey inhibitor therapies for a range of genetically defined diseases.”

The presentation from the SNO 2020 meeting is available on the “Scientific Presentations and Publications” section of the Black Diamond Therapeutics website.

About Black Diamond
Therapeutics

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more information, please visit www.blackdiamondtherapeutics.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the continued development and advancement of BDTX-1535 in IND-enabling studies. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the Company’s product candidate development activities and planned IND-enabling and clinical trials, the Company’s ability to execute on its strategy, regulatory developments in the United States, the Company’s ability to fund operations, and the impact that the current COVID-19 pandemic will have on the Company’s clinical trials, supply chain, and operations, as well as those risks and uncertainties set forth in its 2019 annual report on Form 10-K filed with the United States Securities and Exchange Commission and its other filings filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contacts:

For Investors:

Natalie Wildenradt
[email protected]

For Media:

Kathy Vincent
(310) 403-8951
[email protected]



AGF Announces Estimated Annual Reinvested Capital Gains Distributions for AGF ETFs

TORONTO, Nov. 20, 2020 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF) today announced the estimated annual 2020 reinvested distributions for the AGF ETFs listed on the Toronto Stock Exchange or NEO Exchange. These estimated annual reinvested distributions generally represent realized capital gains within the AGF ETFs and will not be paid in cash, but will be reinvested and reported as taxable.


The annual reinvested distributions will be paid in the form of a notional distribution. A notional distribution is when the units from a reinvested distribution are immediately consolidated with the units held prior to the distribution. The number of units held after the distribution is therefore identical to the number of units held before the distribution. The unitholder’s adjusted cost base for the respective AGF ETF may increase.

Please note that these are estimated capital gains amounts only, up to November 12, 2020. As these are estimated amounts, the final capital gains distributions may change before the AGF ETFs’ December 15, 2020 tax year end. The actual distribution amounts, will be reported on or about December 30, 2020.

The actual taxable amounts for 2020, including the tax characteristics, will be reported in early 2021. Unitholders of record of an AGF ETF on December 31, 2020 will receive the actual 2020 reinvested distributions payable in respect of that AGF ETF on December 31, 2020. Cash distributions for December 2020 will be reported separately.

Details regarding the estimated “per unit” capital gains distribution amounts are as follows:

Fund Name Fund Ticker Exchange Estimated Annual
Reinvested

Capital Gain
Distribution Per Unit
($)

AGF Global Opportunities Bond ETF AGLB NEO Exchange
AGF Global Sustainable Growth Equity ETF AGSG NEO Exchange
AGFiQ Canadian Equity ETF (formerly, AGFiQ Enhanced Core Canadian Equity ETF) QCD Toronto Stock Exchange
AGFiQ Emerging Markets Equity ETF (formerly, AGFiQ Enhanced Core Emerging Markets Equity ETF) QEM Toronto Stock Exchange
AGFiQ Global Balanced ETF Portfolio (formerly, AGFiQMultiAsset Allocation ETF) QMA Toronto Stock Exchange 0.35918
AGFiQ Global ESG Factors ETF (formerly, AGFiQ Enhanced Global ESG Factors ETF) QEF NEO Exchange
AGFiQ Global Income ETF Portfolio (formerly, AGFiQMultiAsset Income Allocation ETF) QMY Toronto Stock Exchange 0.01216
AGFiQ Global Infrastructure ETF (formerly, AGFiQ Enhanced Global Infrastructure ETF) QIF NEO Exchange
AGFiQ Global Multi-Sector Bond ETF (formerly, AGFiQ Enhanced Core Global Multi-Sector Bond ETF) QGB NEO Exchange 0.47547
AGFiQ International Equity ETF (formerly, AGFiQ Enhanced Core International Equity ETF) QIE Toronto Stock Exchange
AGFiQ US Equity ETF (formerly, AGFiQ Enhanced Core US Equity ETF) QUS Toronto Stock Exchange 0.24972
AGFiQ US Market Neutral Anti-Beta CAD-Hedged ETF QBTL Toronto Stock Exchange

Further information about the AGF ETFs can be found at AGF.com.

This information is not intended to provide legal, accounting, tax, investment, financial, or other advice, and should not be relied upon for providing such advice. Commissions, management fees and expenses all may be associated with an investment in exchange-traded funds (ETFs). Please read the prospectus or relevant ETF Facts before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Units of ETFs are bought and sold at market price on a stock exchange and brokerage commissions will reduce returns.

Forward-looking information

This news release contains forward-looking statements with respect to the annual reinvested capital gains distributions for the AGF ETFs. These forward-looking statements involve risks and uncertainties that could cause the actual reinvested capital gains distributions to differ materially from the estimated distributions set forth in this news release. Factors that could cause the actual distributions to differ from the estimated distributions between now and December 15, 2020, (the AGF ETFs’ tax year end) include, but are not limited to: the actual amounts of distributions received by the AGF ETFs; the actual amounts of capital gains generated from sales of securities; trading activity within the AGF ETFs, including buying and selling of securities; and subscription and redemption activity, as applicable.

About AGF Management Limited

Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. AGF brings a disciplined approach to delivering excellence in investment management through its fundamental, quantitative, alternative and high-net-worth businesses focused on providing an exceptional client experience. AGF’s suite of investment solutions extends globally to a wide range of clients, from financial advisors and individual investors to institutional investors including pension plans, corporate plans, sovereign wealth funds and endowments and foundations.

AGF has investment operations and client servicing teams on the ground in North America, Europe and Asia. With over $36 billion in total assets under management, AGF serves more than one million investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.

Media Contact

Amanda Marchment
Director, Corporate Communications
416-865-4160
[email protected]



Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action

NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Nov. 20, 2020 (GLOBE NEWSWIRE) — via NewMediaWire  — Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced positive in vitro data by its joint venture partner NLC Pharma for the Company’s dietary supplement Tollovid™, demonstrating its ability to inhibit the 3CL protease. The 3CL protease is an enzyme that is required for the intracellular replication of coronaviruses. Tollovid received a certificate of free sale from the FDA in August 2020 and is being launched commercially into the US market initially at botanical wellness store The Alchemist’s Kitchen™ in New York City.

As part of NLC Pharma’s development activities for Tollovid, a joint study was conducted in the laboratory of Professor Dan Farr, Vice President of Research and Development at Tel Aviv University. During the study, the ability to inhibit the activity of enzyme 3CL was examined. The researchers believe the 3CL protease plays a key role in coronavirus activity and is critical to allow for processing of the proteins encoding viral RNA. Inhibition of this activity could stop the ability of coronaviruses to replicate, and thus inhibit their ability to spread in the body. During the study it was shown that Tollovid, which is an extract of a botanical substance, was able to successfully inhibit the 3CL protease activity.

Since the beginning of 2020, over 1,000 patients suffering from diseases caused by circulating coronaviruses in Israel have received various dosing regimens of Tollovid, including both hospitalized and non-hospitalized patients. There has been overwhelmingly positive customer feedback on their experience with the product, including significant positive feedback from physicians.  Based on the results of this market research study conducted in Israel, as well as the pioneering research advanced by Dr. Dorit Arad on the entire coronavirus family of viruses for over the last 20 years, NLC Pharma is preparing to initiate a randomized clinical trial in Israel in December 2020 to evaluate the potential for Tollovid to treat patients suffering from actively circulating coronaviruses.

For information related to Todos Medical’s COVID-19 testing capabilities, please visit www.todoscovid19.com

For testing and PPE inquiries, please email [email protected] .

About Tollovid™

Tollovid is an orally administered proprietary blend of plant extracts that includes a powerful 3CL protease inhibitor that helps support and maintain healthy immune function.

About The Alchemist’s Kitchen

The Alchemist’s Kitchen is a plant-based wellness brand dedicated to the education of consumers to the potential benefits of botanical medicines and herbal remedies. It develops and markets proprietary formulations via retail and online channels of distribution. The Alchemist’s Kitchen flagship storefront is located at 119 Crosby St, New York, NY 10003. The Company’s website is www.thealchemistskitchen.com.

About Todos Medical Ltd.

Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the third quarter of 2020.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer’s disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Additionally, Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID-19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Todos has formed strategic partnerships with Integrated Health LLC, MOTOPARA Foundation to deploy mobile COVID-19 testing in the United States.

For more information, please visit https://www.todosmedical.com/.

Forward-looking Statements

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Investor Contact:

Kim Sutton Golodetz

LHA Investor Relations

Senior Vice President

(212) 838-3777

[email protected]

Todos Corporate Contact:

Priyanka Misra

Todos Medical

(917) 983-4229 ext. 103

[email protected]



Conversion Labs Appoints Expert Life Sciences Attorney, Eric H. Yecies, as Chief Compliance Officer and General Counsel

NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) — Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has appointed expert Life Sciences attorney, Eric H. Yecies, to the new position of chief compliance officer and general counsel.

Yecies is a highly accomplished trial and transactional attorney with over 16 years of experience practicing law in the life sciences space. He was previously a partner at Holland & Knight, a top ranked national law firm. Yecies was a member of its Intellectual Property Group, and grew its New York IP Group from inception. He focused his practice on high-profile cases in the pharmaceutical, chemical, biotechnology and medical device industries.

Yecies specialized in patent, trade secret, trademark, false advertising, anti-competitive, counterfeiting, and regulatory cases across a broad range of technical disciplines. He has extensive knowledge and experience with the Drug Price Competition and Patent Term Restoration Act, which establishes a commercial approval pathway for generic drug products through submission of an abbreviated new drug application. Yecies is also experienced in contract, tort, bankruptcy, real estate, and corporate transactions.

“Continuing to build a best-in-class compliance infrastructure is a critical piece of our long-term success in telemedicine,” stated Conversion Labs CEO, Justin Schreiber. “Eric’s deep experience in the healthcare, regulatory, and commercial product world will ensure that we lead the industry in best practices and compliance. Eric will also work closely with our medical and advertising teams to support ongoing regulatory adherence, which is an important part of our mission to deliver the highest quality of care to our patients.”

Prior to Holland & Knight, Yecies was a senior patent litigation associate Goodwin Procter, where he was responsible for running day-to-day strategy and management of billion-dollar IP cases, as well as negotiating settlement and licensing agreements on behalf of life science companies.

“I’m very excited to join Conversion Labs at this pivotal stage in the company’s growth and the emergence of telemedicine,” commented Yecies. “Conversion Labs has established itself as a pioneer in the telehealth industry, and I believe that the company’s innovative platform will continue to generate considerable growth. I’m honored to be a part of its strategically expanding team, and to use my life sciences legal background to strengthen the company’s foundation and support maximum growth moving forward.”

Yecies received his Doctor of Law, specializing in intellectual property, from the New York University School of Law. He received his B.A. and M.A. in biology, molecular concentration, from the University of Pennsylvania. He regularly speaks and publishes about intellectual property law.

About Conversion Labs
Conversion Labs, Inc. is a telemedicine company with a portfolio of online direct-to-consumer brands. The company’s brands combine virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S. To learn more, visit Conversionlabs.com.

Important Cautions Regarding Forward-Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things our plans, strategies and prospects — both business and financial. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Many of the forward-looking statements contained in this news release may be identified by the use of forward-looking words such as “believe,” “expect,” “anticipate,” “should,” “planned,” “will,” “may,” “intend,” “estimated,” and “potential,” among others. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include market conditions and those set forth in reports or documents that we file from time to time with the United States Securities and Exchange Commission. All forward-looking statements attributable to Conversion Labs, Inc. or a person acting on its behalf are expressly qualified in their entirety by this cautionary language.

Company Contact                                
Conversion Labs                                
Juan Manuel Piñeiro Dagnery                        
CFO                                                
Email Contact        

Media and Investor Relations Contact

Ron Both or Grant Stude
CMA Investor Relations
Tel (949) 432-7566
Email Contact



BCT-Bank of Charles Town Food Drive, Donating $5 Per Pound of Food Up To $10,000

PR Newswire

CHARLES TOWN, W.Va., Nov. 20, 2020 /PRNewswire/ — (OTC:PTBS) –BCT-Bank of Charles Town, also known as The Community’s Bank, through its BCTCares For The Hungry initiative, recently launched a food drive to support the impact of the COVID-19 pandemic on local families’ food insecurity. Additionally, BCT will donate $5 for every pound of food donated, up to $10,000. The food drive concludes December 4, 2020.  Food donations can be left at collection receptacles at any BCT branch. 

“Our employee-driven BCTCares committee identified the sustained threat to many of our neighbors’ ability to feed their families as a result of the persistent COVID-19 pandemic,” stated Alice Frazier, President and CEO. “As a result, they launched a food drive in which our Board agreed to donate $5 for every pound of food collected, up to $10,000.  We encourage our patrons and neighbors to drop off food at any of our branch locations.”

A list of food items being collected can be found on BCT’s website at www.mybct.bank. Both the monetary donations from BCT and the food collected from patrons will be distributed to local charities who directly support the needs of food insecure families. They are as follows:

Berkeley County, WV:

Berkeley County Meals on Wheels

Berkeley County Backpack Program

CCAP Loaves and Fishes

Jefferson County, WV: 

Jefferson County Meals on Wheels

Jefferson County Community Ministries   

Loudoun County, VA:   

Loudoun Hunger Relief

Loudoun Education Foundation – Backpack Program

Washington County, MD: 

Washington County Commission on Aging – Meals on Wheels 

“BCTCares For The Hungry” uses hashtag #BCTCares for social media postings about activities related to these initiatives.

About the Company

Founded in 1871, BCT – Bank of Charles Town, also known as The Community’s Bank, is a wholly owned subsidiary of Potomac Bancshares, Inc. (OTC:PTBS). With approximately $631 million in assets as of September 30, 2020, the Company conducts operations through its main office, an additional eight branch offices, and one loan production office.  BCT’s offices are located in Jefferson and Berkeley Counties (WV), Washington County (MD), and Loudoun County (VA). The Bank provides various banking products and services including free access to over 55,000 ATMs through the Allpoint® network plus online and mobile banking for individuals, businesses, and local governments. The Bank also offers commercial lines and term loans, residential and commercial construction, commercial real estate loans and agricultural loans. The Residential Lending division offers secondary market and portfolio mortgage loans, one-time close construction to perm loans, as well as home equity loans and lines of credit. For over 60 years, BCT Wealth Advisors has provided financial management, investment, trust, and estate services to its clients. In 2019 and 2020, the Bank was named a “Best Bank To Work For” by American Banker.  In 2018, Forbes named BCT a “Best In State Bank” for Maryland.

The Company’s shares are quoted on the OTC Pink Sheet marketplace under the symbol “PTBS.” For more information about Potomac Bancshares, Inc., and the Bank, please visit our website at www.mybct.bank.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bct-bank-of-charles-town-food-drive-donating-5-per-pound-of-food-up-to-10-000–301177956.html

SOURCE BCT – Bank of Charles Town